Company intelligence / Profile preview
SNIPR Biome
Copenhagen, Denmarksniprbiome.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Phase 1
01
Overview
SNIPR Biome was the first company to orally dose humans with a CRISPR therapeutic. Their lead candidate SNIPR001 has received FDA Fast Track Designation and is in Phase 1 clinical trials targeting E. coli in patients with hematological malignancy at risk of neutropenia[2][3].
- Therapeutic areas
- GastroenterologyOncologyInfectious Diseases
- Modalities
- CRISPR-based microbial gene therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Novo Nordisk A/SCARB-XBill & Melinda Gates FoundationSPRIN-DMD Anderson Cancer Center[3]
Beyond the preview
Go deeper on SNIPR Biome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNIPR Biome.